Time To Buy The Dip In Boston Scientific Stock?
Boston Scientific (BSX) stock has fallen by 15.8% in less than a month, from $59.95 on 27th Apr, 2026 to $50.46 now. Should you buy this dip?
Dip buying is a viable strategy for quality stocks that have a history of recovering from dips. As it turns out, BSX stock passes basic quality checks. Historically, the median return for the 12-month period following sharp dips was 12% , with median peak return reaching 20%. We define sharp dip as stock going down 20% or more, in less than 30 day period.
Below, we get into details of historical dips and subsequent returns.
Historical Median Returns Post Dips
- How Low Can BSX Really Go In A Market Crash?
- Is BSX Stock A Value Trap Or A Rebound Play?
- Stronger Bet Than IDEXX Laboratories Stock: DXCM, BSX Deliver More
- Why BSX Could Outperform Stryker Stock
- Why DXCM, BSX Could Outperform Edwards Lifesciences Stock
- Time To Buy The Dip In Boston Scientific Stock?
| Period | Past Median Return |
|---|---|
| 1M | 1.0% |
| 3M | -7.0% |
| 6M | 4.9% |
| 12M | 11.7% |
Historical Dip-Wise Details
BSX had 6 events since 1/1/2010 where the dip threshold of -20% within 30 days was triggered
- 20% median peak return within 1 year of dip event
- 188 days is the median time to peak return after a dip event
- -17% median max drawdown within 1 year of dip event
| 30 Day Dip | BSX Subsequent Performance | |||||||
|---|---|---|---|---|---|---|---|---|
| Date | BSX | SPY | 1Y | Peak Return |
Max Drop |
# Days to Peak |
||
| Median | 12% | 20% | -17% | 188 | ||||
| 5082026 | -23% | 14% | -6% | 7% | -6% | 14 | ||
| 2042026 | -21% | 1% | -33% | 3% | -33% | 1 | ||
| 11232020 | -21% | 1% | 21% | 38% | -1% | 252 | ||
| 3092020 | -21% | -17% | 16% | 24% | -24% | 177 | ||
| 6042010 | -20% | -12% | 20% | 37% | -11% | 200 | ||
| 3152010 | -21% | 8% | 7% | 15% | -25% | 281 | ||
1Y Refers to 1 year or time since recent dip, whichever is smaller
While the table provides a good summary of past dips for BSX stock, isolating dips and subsequent recovery during major market crashes is another critical piece of information.
Boston Scientific Passes Basic Financial Quality Checks
Revenue growth, profitability, cash flow, and balance sheet strength need to be evaluated to reduce the risk of a dip being the sign of a deteriorating business situation.
| Quality Metrics | Value | Quality Check |
|---|---|---|
| Revenue Growth (LTM) | 17.4% | Pass |
| Revenue Growth (3-Yr Avg) | 16.5% | Pass |
| Operating Cash Flow Margin (LTM) | 21.1% | Pass |
| Leverage (see below) | – | Pass |
| => Interest Coverage Ratio | 11.5 | |
| => Cash To Interest Expense Ratio | 4.1 |
While these are some basic checks required for conviction, there is a lot more to unpack before taking any investment decision.
Staying Invested Over Timing the Bottoms
Buying the dip on a stock like BSX looks easy on a historical chart, but living through it is a high-stakes game. When a “bargain” keeps dipping, the volatility often forces investors to lose their nerve and exit right before the recovery begins. To actually capture that upside, you need a strategy that makes “staying invested” a mechanical reality rather than a test of willpower.
The Trefis High Quality Portfolio (HQ) is engineered to give you that staying power. By diversifying across 30 quality stocks, it dampens the stomach-churning drops of a market dip while retaining upside exposure. The HQ strategy has outpaced the S&P 500, S&P Mid-cap, and Russell 2000, and has returned > 105% since inception.